jnj-55308942
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 3, 2017 (NCT03151486)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 7ANTAGONIST
P2RX7 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1Cc2c(nnn2-c2ncc(F)cn2)CN1C(=O)c1ccnc(C(F)(F)F)c1F- Mol. weight
- 425.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3914857 ↗
Also known as
- jnj-55308942
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05328297 | Phase 2 | Jun 3, 2022 | Janssen Pharmaceutica NV |
| NCT03547024 | Phase 1 | Jun 8, 2018 | Johnson and Johnson |
| NCT03437590 | Phase 1 | Mar 15, 2018 | Johnson and Johnson |
| NCT03151486 | Phase 1 | May 3, 2017 | Johnson and Johnson |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 3 | 3 | 1 | 2017 |
| Janssen Pharmaceutica NV | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1